NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Sees Large Growth in Short Interest

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) was the recipient of a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 230,100 shares, an increase of 42.7% from the January 31st total of 161,300 shares. Currently, 1.6% of the shares of the company are short sold. Based on an average daily volume of 273,600 shares, the short-interest ratio is currently 0.8 days.

Wall Street Analysts Forecast Growth

Separately, Maxim Group reiterated a “hold” rating on shares of NeuroSense Therapeutics in a report on Monday, December 16th.

NeuroSense Therapeutics Stock Up 4.8 %

Shares of NeuroSense Therapeutics stock traded up $0.05 during trading on Tuesday, reaching $1.10. The company’s stock had a trading volume of 182,710 shares, compared to its average volume of 247,411. The business’s 50-day moving average price is $1.13 and its 200-day moving average price is $1.12. The firm has a market cap of $15.03 million, a PE ratio of -1.72 and a beta of 1.27. NeuroSense Therapeutics has a 52 week low of $0.51 and a 52 week high of $2.25.

NeuroSense Therapeutics (NASDAQ:NRSN) last announced its earnings results on Wednesday, December 18th. The company reported ($0.11) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On NeuroSense Therapeutics

A number of institutional investors have recently modified their holdings of NRSN. XTX Topco Ltd lifted its position in NeuroSense Therapeutics by 40.9% during the third quarter. XTX Topco Ltd now owns 45,996 shares of the company’s stock worth $58,000 after purchasing an additional 13,346 shares during the period. Jane Street Group LLC acquired a new position in shares of NeuroSense Therapeutics in the fourth quarter valued at approximately $78,000. Finally, Citadel Advisors LLC increased its stake in shares of NeuroSense Therapeutics by 640.9% in the fourth quarter. Citadel Advisors LLC now owns 253,997 shares of the company’s stock valued at $305,000 after buying an additional 219,717 shares during the period. Institutional investors own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.